162 related articles for article (PubMed ID: 22360854)
1. ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
Wang F; Liang YJ; Wu XP; Su XD; Fu LW
Chin J Cancer; 2012 Mar; 31(3):150-8. PubMed ID: 22360854
[TBL] [Abstract][Full Text] [Related]
2. ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Zhang W; Chen Z; Chen L; Wang F; Li F; Wang X; Fu L
Sci Rep; 2017 Jan; 7():40064. PubMed ID: 28059154
[TBL] [Abstract][Full Text] [Related]
3. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
4. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
6. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
7. The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
Narayanan S; Gujarati NA; Wang JQ; Wu ZX; Koya J; Cui Q; Korlipara VL; Ashby CR; Chen ZS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671108
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
9. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
10. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
15. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
Holland ML; Lau DT; Allen JD; Arnold JC
Br J Pharmacol; 2007 Nov; 152(5):815-24. PubMed ID: 17906686
[TBL] [Abstract][Full Text] [Related]
16. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
[TBL] [Abstract][Full Text] [Related]
17. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
19. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
